A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Contact:

NCT Number:

Protocol:

AAAR9532

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

that is known to play a role in the growth and survival of cancer cells in different types of leukemia.The purpose of this study is to determine the safety, recommended dose and preliminary activity of MS-553 in treating CLL/SLL.

Are you Eligible? (Inclusion Criteria)

  • Are you at least 18 years of age?
  • Do you have CLL or SLL?

Specialty Area(s)

Chronic Lymphocytic Leukemia

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032